Cancers

Journal Browser

► Journal Browser

Image-Guided Percutaneous Laser Ablation of Solid Tumors in Urology Application

Share This Special Issue

Special Issue Editors

Special Issue Information

Dear Colleagues,

Over the last two decades, the need for efficacious procedures with a low risk of complications has increases the employment of minimally invasive techniques for treating solid tumors instead of more aggressive surgical treatments. Among these techniques, the percutaneous laser ablation procedure has proven to be among the most micro-invasive owing to the use of extremely thin needles to reach the target tissue to be destroyed. This procedure can be used in different organs for many indications (malignant mass, as well as benign ones), as proven by available clinical evidence.

We are pleased to invite you to take part in the publication of this Special Issue by sharing your experience/research, with the aim to collect additional efficacy and safety data relating to techniques for the laser ablation of tumors in urology district from different.

In this Special Issue, original research articles and reviews on the percutaneous laser ablation technique are welcome. Research areas may include (but are not limited to) the following: prostate cancer and kidney cancer.

I look forward to receiving your contributions.

Prof. Dr. Guglielmo Manenti
Dr. Eric M. Walser
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

percutaneous laser ablation
organ-sparing technique
micro-invasive procedure
FLA
TPLA
prostate
kidney

Published Papers (1 paper)

Research

14 pages, 3124 KiB

Open AccessArticle

Transperineal Laser Ablation (TPLA) Treatment of Focal Low–Intermediate Risk Prostate Cancer

by Gugliemo Manenti, Tommaso Perretta, Marco Nezzo, Federico Romeo Fraioli, Beatrice Carreri, Paola Elda Gigliotti, Andrea Micillo, Andrea Malizia, Daniele Di Giovanni, Colleen Patricia Ryan and Francesco Giuseppe Garaci

Cancers 2024, 16(7), 1404; https://doi.org/10.3390/cancers16071404 - 3 Apr 2024

Viewed by 935

Abstract

Background: This interventional pilot study aimed to evaluate the short-term (3 years) efficacy of focal laser ablation (FLA) in treating the index lesion of low–intermediate-risk prostate cancer, along with assessing the safety of the procedure (ClinicalTrials.gov ID NCT04045756). Methods: Forty patients aged between 46 and 86 with histologically proven organ-confined prostate cancer and low-to-intermediate progression risk were included. FLA was performed under percutaneous fusion magnetic resonance/ultrasound guidance in a Day Hospital setting under local anesthesia. Patients underwent regular clinical and functional assessments through the international index of erectile function (IIEF-5) and the International Prostatism Symptom Score (IPSS), PSA measurements, post-procedure MRI scans, and biopsies at 36 months or if positive findings were detected earlier. Statistical analyses were conducted to assess trends in PSA levels and cavity dimensions over time. Results: Forty patients were initially included, with fifteen lost to follow-up. At 36 months, a mean PSA reduction of 60% was observed, and 80% of MRI scans showed no signs of in-field clinically significant residual/recurrent cancer. Biopsies at 36 months revealed no malignant findings in 20 patients. No deterioration in sexual function or urinary symptoms was recorded. Conclusions: FLA appears to be safe, feasible, and effective in the index lesion treatment of low–intermediate-risk prostate cancer, with a high rate of tumor eradication and preservation of quality of life. Full article

(This article belongs to the Special Issue Image-Guided Percutaneous Laser Ablation of Solid Tumors in Urology Application)

► Show Figures